Analysis Tools
digestive/alimentary system
|
• diarrhea with bloody feces is seen in mice with intestinal inflammation
|
|
• numerous neutrophilic crypt abscesses are detected in several mice with intestinal inflammation
|
|
• inflammation results in extensive destruction of the mucosa with crypts separated from each other and from the lamina muscularis propria by the infiltrating cells
• outside of inflammatory lesions the colonic mucosa appears normal with the exception of an increase in mast cell numbers
|
|
• in mice with intestinal inflammation
|
|
• in all mice, regardless of pIpC treatment
• severity of inflammation varies and severe inflammation is more common in older mice
• inflammatory changes affect sharply demarcated patches of the mucosa and in most mice occur in long stretches of the mucosa
• most lesions are found in the cecum and ascending colon
• lesions are characterized by a massive infiltration of T cells, B cells, macrophages, and neutrophils with high numbers of mast cells found in the crypt epithelium surrounding the lesion
• the surface epithelium shows erosions in several mice
|
|
• in a few mice, regardless of pIpC treatment
|
hematopoietic system
|
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen
|
|
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age
• pIpC treated mice display a variable increase in cutaneous mast cell numbers
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes, spleen, liver and/or stomach
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
|
|
• bone marrow cells are unable to engraft in nonirradiated recipient mice
|
neoplasm
|
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size
• in a few mice these tumors are macroscopically visible
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
|
growth/size/body
weight loss
(
J:169611
)
|
• in mice with intestinal inflammation
|
integument
|
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size
• in a few mice these tumors are macroscopically visible
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
|
immune system
|
• in all mice, regardless of pIpC treatment
• severity of inflammation varies and severe inflammation is more common in older mice
• inflammatory changes affect sharply demarcated patches of the mucosa and in most mice occur in long stretches of the mucosa
• most lesions are found in the cecum and ascending colon
• lesions are characterized by a massive infiltration of T cells, B cells, macrophages, and neutrophils with high numbers of mast cells found in the crypt epithelium surrounding the lesion
• the surface epithelium shows erosions in several mice
|
|
• in a few mice, regardless of pIpC treatment
|
|
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen
|
|
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age
• pIpC treated mice display a variable increase in cutaneous mast cell numbers
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes, spleen, liver and/or stomach
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
|
endocrine/exocrine glands
|
• numerous neutrophilic crypt abscesses are detected in several mice with intestinal inflammation
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| mastocytosis | DOID:350 |
OMIM:154800 |
J:169611 | |
